{"name":"MEDA Pharma GmbH & Co. KG","slug":"meda-pharma-gmbh-co-kg","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":5,"colorKey":"immunology","drugs":[{"name":"Formatris 12µg","genericName":"Formatris 12µg","slug":"formatris-12-g","indication":"Other","status":"phase_2"},{"name":"fluticasone propionate nasal spray + loratadine","genericName":"fluticasone propionate nasal spray + loratadine","slug":"fluticasone-propionate-nasal-spray-loratadine","indication":"Allergic rhinitis (seasonal and perennial)","status":"marketed"},{"name":"Azelastine mono","genericName":"Azelastine mono","slug":"azelastine-mono","indication":"Other","status":"phase_1"},{"name":"Foradil P 12µg","genericName":"Foradil P 12µg","slug":"foradil-p-12-g","indication":"Other","status":"phase_2"},{"name":"oxetacaine","genericName":"oxetacaine","slug":"oxetacaine","indication":"Other","status":"discontinued"}]},{"name":"Respiratory","slug":"respiratory","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"neuroscience","drugs":[{"name":"Combination DSCG and Reproterol","genericName":"Combination DSCG and Reproterol","slug":"combination-dscg-and-reproterol","indication":"Asthma","status":"phase_2"},{"name":"Foradil P 24µg","genericName":"Foradil P 24µg","slug":"foradil-p-24-g","indication":"Asthma","status":"phase_2"}]},{"name":"Cardiovascular","slug":"cardiovascular","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Flecainide controlled release","genericName":"Flecainide controlled release","slug":"flecainide-controlled-release","indication":"Paroxysmal supraventricular tachycardia (PSVT)","status":"marketed"}]},{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"cardiovascular","drugs":[{"name":"Aldara (Imiquimod)","genericName":"Aldara (Imiquimod)","slug":"aldara-imiquimod","indication":"Genital warts (external)","status":"phase_3"}]}],"pipeline":[{"name":"Flecainide controlled release","genericName":"Flecainide controlled release","slug":"flecainide-controlled-release","phase":"marketed","mechanism":"Flecainide is a Class IC antiarrhythmic that blocks cardiac sodium channels to slow conduction velocity and suppress abnormal electrical activity in the heart.","indications":["Paroxysmal supraventricular tachycardia (PSVT)","Paroxysmal atrial fibrillation","Ventricular arrhythmias"],"catalyst":""},{"name":"Formatris 12µg","genericName":"Formatris 12µg","slug":"formatris-12-g","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"fluticasone propionate nasal spray + loratadine","genericName":"fluticasone propionate nasal spray + loratadine","slug":"fluticasone-propionate-nasal-spray-loratadine","phase":"marketed","mechanism":"This combination reduces allergic rhinitis symptoms by suppressing nasal inflammation via corticosteroid action and blocking histamine-mediated allergic responses via H1-receptor antagonism.","indications":["Allergic rhinitis (seasonal and perennial)"],"catalyst":""},{"name":"Aldara (Imiquimod)","genericName":"Aldara (Imiquimod)","slug":"aldara-imiquimod","phase":"phase_3","mechanism":"Imiquimod is a toll-like receptor 7 (TLR7) agonist that activates innate immune responses to treat viral infections and skin cancers.","indications":["Genital warts (external)","Actinic keratosis","Superficial basal cell carcinoma"],"catalyst":""},{"name":"Azelastine mono","genericName":"Azelastine mono","slug":"azelastine-mono","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Combination DSCG and Reproterol","genericName":"Combination DSCG and Reproterol","slug":"combination-dscg-and-reproterol","phase":"phase_2","mechanism":"DSCG inhibits mast cell degranulation and reduces inflammation, while Reproterol is a beta-2 adrenergic receptor agonist that relaxes bronchial smooth muscle.","indications":["Asthma","Chronic obstructive pulmonary disease (COPD)"],"catalyst":""},{"name":"Foradil P 12µg","genericName":"Foradil P 12µg","slug":"foradil-p-12-g","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Foradil P 24µg","genericName":"Foradil P 24µg","slug":"foradil-p-24-g","phase":"phase_2","mechanism":"Foradil P 24µg is a long-acting beta2-adrenergic receptor agonist (LABA) used to control and prevent bronchospasm in patients with asthma and COPD.","indications":["Asthma","Chronic obstructive pulmonary disease (COPD)"],"catalyst":""},{"name":"oxetacaine","genericName":"oxetacaine","slug":"oxetacaine","phase":"discontinued","mechanism":"Sodium channel alpha subunits; brain (Types I, II, III)","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMi-AFBVV95cUxOWUJ2QmtHSnNEUEJ5LVA0LWVYX2l6Y2JsUEdReDBXLTVhVVpBeGxwR2ctRnFhN3YwSGFNWG94UUdiNGhXZmd5bXFtdlBrcFUxY3dtczI5WTZDRzV4anFhUTFUNVBqbndkOGtVcFhPVkc1elQybUdzMkM0bVl0R2FPRGN2dzlwX0NLcFlzdUhlYmxQQ2Q4OThQYThVSHdsZmZNT0lVNV81YTVVSGNWRHNXNGs1T0l4Q18wSG1FYXlnUW41TXNQUGZNa3p0V3FENFoxSjB6WXJ1MVRObmx6RUdkaURGb3lKam5OaUhDZTNEcnYzZkVYTDRxag?oc=5","date":"2013-03-18","type":"pipeline","source":"prnewswire.com","summary":"BioDelivery Sciences Provides Business Review and Update in Conjunction with Filing of its 2012 Annual Report - prnewswire.com","headline":"BioDelivery Sciences Provides Business Review and Update in Conjunction with Filing of its 2012 Annual Report","sentiment":"neutral"}],"patents":[],"drugCount":9,"phaseCounts":{"marketed":2,"phase_2":4,"phase_3":1,"phase_1":1,"discontinued":1},"enrichmentLevel":0,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}